| Value | ₹52.75 Cr |
|---|
BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹731.70
- Market cap
- ₹11,517 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.5×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Akums Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Other legal & regulatory announcements
All →Morarka Finance Legal & Regulatory
Morarka Finance received a BSE fine of Rs.1,22,720 inclusive of GST for late filing of its FY2025-26 annual report. The company disputes intent and has sought a waiver.
- Value
- ₹0.01 Cr
Stanpacks (India) Legal & Regulatory
BSE fined Stanpacks India Rs 2,360 including GST for late annual report submission under Regulation 34. The company has paid the penalty and committed to future compliance.
- Value
- ₹0.00 Cr
Sofcom Systems Legal & Regulatory
Sofcom Systems received a BSE fine of Rs.4,720 including GST for late annual report filing. The company says the impact is limited to the fine.
- Value
- ₹0.00 Cr
Ashima Legal & Regulatory
Ashima withdrew its civil suit against HDFC Bank, with about Rs.4.06 Crore to be paid back. The withdrawal concludes settlement proceedings with HDFC Bank.
- Value
- ₹4.06 Cr
Bajaj Electricals Legal & Regulatory
Bajaj Electricals received a Rs. 112.32 crore income tax demand for AY 2019-20. The company is evaluating legal remedies, with no operational impact.
- Value
- ₹112.3 Cr
Samvardhana Motherson International Legal & Regulatory
Samvardhana Motherson's Spanish subsidiary faces a proposed EUR 20,001 fine for air quality breaches. The company reports no material financial or operational impact.
- Value
- ₹0.21 Cr